You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Consolidation phase

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

HIV, Burkitt's Lymphoma Trial in Italy (Induction Phase, Consolidation Phase (on day +50), Intensification phase)

Completed
  • HIV
  • Burkitt's Lymphoma
  • Induction Phase
  • +4 more
  • Aviano (PN), Italy
  • +7 more
Aug 2, 2022

Physical Exercise, Motor Learning Trial in Lyon (Sleep Deprivation (SD), Normal Night (Night), Physical Exercise (HIIE))

Recruiting
  • Physical Exercise
  • Motor Learning
  • Sleep Deprivation (SD)
  • +5 more
  • Lyon, France
    Service d'explorations fonctionnelles respiratoires-Médecine du
Jun 19, 2023

NSCLC Trial in Guangzhou (Hypofractionated radiotherapy, induction chemo-immunotherapy, concurrent chemo)

Recruiting
  • Non-small Cell Lung Cancer
  • Hypofractionated radiotherapy
  • +4 more
  • Guangzhou, Guangdong, China
    Sun yat-sen university cancer center
Nov 14, 2023

NSCLC, Consolidation Immunotherapy, Radiotherapy or Sequential Chemoradiation Trial in Beijing (Tislelizumab)

Recruiting
  • Non-small Cell Lung Cancer
  • +2 more
  • Beijing, China
    Peking University Cancer Hospital and Institute
Mar 4, 2023

Myocardial Infarction Trial (other, diagnostic test, device)

Not yet recruiting
  • Myocardial Infarction
  • Therapeutic educational consolidation program in Phase 3 of cardiac rehabilitation associating a patient & caregiver partnership
  • +8 more
  • (no location specified)
Jun 30, 2023

Multiple Myeloma, Myeloma-Associated Amyloidosis Trial in Saint Louis (Selinexor, Lenalidomide, Dexamethasone)

Not yet recruiting
  • Multiple Myeloma
  • Myeloma-Associated Amyloidosis
  • Saint Louis, Missouri
    Washington University School of Medicine
Apr 6, 2023

Limited-stage Small Cell Lung Cancer (LS-SCLC) Trial in Jinan (Tifcemalimab injection, toripalimab injection, Placebo for

Not yet recruiting
  • Limited-stage Small Cell Lung Cancer (LS-SCLC)
  • Tifcemalimab injection
  • +3 more
  • Jinan, Shandong, China
    Shandong Cancer Hospital & Institute
Oct 18, 2023

Acute Myeloid Leukemia, Acute Myeloid Leukemia Recurrent, Leukemia Trial in Boston (Cytokine-Induced Memory-like Natural Killer

Not yet recruiting
  • Acute Myeloid Leukemia
  • +3 more
  • Cytokine-Induced Memory-like Natural Killer Cells
  • +2 more
  • Boston, Massachusetts
  • +1 more
Nov 22, 2023

Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission Trial (Asciminib, Imatinib)

Not yet recruiting
  • Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission
  • (no location specified)
Jun 7, 2022

NSCLC Trial (Durvalumab)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • (no location specified)
Jun 22, 2023

Acute Myeloid Leukemia, MDS Trial in Ulm (drug, combination product, other)

Recruiting
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndromes
  • Berlin, Germany
  • +9 more
Jan 13, 2023

Stage IIIA NSCLC Trial in Cleveland (Cisplatin, Etoposide, Pembrolizumab)

Terminated
  • Stage IIIA Non-Small Cell Lung Cancer
  • Cleveland, Ohio
    Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Ca
Dec 15, 2022

Locally Advanced NSCLC, Efficacy and Safety Trial in Guangzhou (Anlotinib, Chemotherapy, Radiotherapy)

Recruiting
  • Locally Advanced Non-small Cell Lung Cancer
  • Efficacy and Safety
  • Guangzhou, Guangdong, China
    Sun yat-sen University Cancer Center
Jul 28, 2022

Limited Stage Small Cell Lung Cancer Trial (HLX10, hypofractionated radiotherapy, Prophylactic Cranial Irradiation (PCI))

Not yet recruiting
  • Limited Stage Small Cell Lung Cancer
  • (no location specified)
Jun 29, 2022

Lung Cancer, Extensive-stage Small-cell Lung Cancer, Radiotherapy Trial (Durvalumab + carboplatin/cisplatin + etoposide,

Not yet recruiting
  • Lung Cancer
  • +2 more
  • Durvalumab + carboplatin/cisplatin + etoposide
  • +2 more
  • (no location specified)
Aug 3, 2022

Large B-cell Lymphoma, Lymphoma Trial in Houston (Loncastuximab Tesirine)

Not yet recruiting
  • Large B-cell Lymphoma
  • Lymphoma
  • Loncastuximab Tesirine
  • Houston, Texas
    MD Anderson Cancer Center
Jul 14, 2022

Limited Stage Small Cell Lung Cancer Trial in Guangzhou (Sugemalimab, Placebo)

Not yet recruiting
  • Limited Stage Small Cell Lung Cancer
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Nov 12, 2022

NSCLC Trial in Philadelphia (Pembrolizumab)

Active, not recruiting
  • Non-small Cell Lung Cancer
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of the University of Pennsylvania
Nov 1, 2022

Limited Stage Small Cell Lung Cancer Trial in Shanghai (Pamiparib)

Recruiting
  • Limited Stage Small Cell Lung Cancer
  • Shanghai, Shanghai, China
  • +1 more
Jul 29, 2022

Lung Cancer, Wedge Resection, Ground-glass Opacity Trial in Shanghai (Wedge resection)

Not yet recruiting
  • Lung Cancer
  • +2 more
  • Wedge resection
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Oct 25, 2023

Relapsed/Refractory Multiple Myeloma Trial in Philadelphia (Cevostamab)

Not yet recruiting
  • Relapsed/Refractory Multiple Myeloma
  • Philadelphia, Pennsylvania
    Hospital of the University of Pennsylvania
Apr 7, 2023

Breast Cancer Trial in France, Germany (Intraoperative radiotherapy (IORT))

Active, not recruiting
  • Breast Cancer
  • Intraoperative radiotherapy (IORT)
  • Montpellier, France
  • +3 more
May 30, 2022

NSCLC, Stage III Trial (SHR-1701)

Not yet recruiting
  • NSCLC, Stage III
  • (no location specified)
Dec 14, 2021

Rectal Cancer Trial in Mecca (Chemotherapy)

Recruiting
  • Rectal Cancer
  • Mecca, Makkah Western, Saudi Arabia
    King Abdullah Medical City, Holy Capital
Apr 5, 2022

Nasopharyngeal Carcinoma Trial in Guangzhou (Camrelizumab, gemcitabin, cisplatin, Stereotactic Body Radiotherapy, Intensity

Recruiting
  • Nasopharyngeal Carcinoma
  • Camrelizumab, gemcitabin, cisplatin
  • Stereotactic Body Radiotherapy, Intensity modulated-radiotherapy
  • Guangzhou, Guangdong, China
    Department of Nasopharyngeal Carcinoma, Sun Yat-sen University C
Jun 19, 2022